国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
16期
2542-2544
,共3页
谢鹤%李贵才%吴淑庄%王朋朋%黄斌%钱月梅
謝鶴%李貴纔%吳淑莊%王朋朋%黃斌%錢月梅
사학%리귀재%오숙장%왕붕붕%황빈%전월매
白三烯%过敏性紫癜%孟鲁斯特
白三烯%過敏性紫癜%孟魯斯特
백삼희%과민성자전%맹로사특
Leukotriene%Henoch-Schonlein purpura%Montelukast
目的 研究白三烯受体拮抗剂孟鲁斯特治疗小儿过敏性紫癜的临床疗效.方法 将120例过敏性紫癜患儿随机分成两组,对照组采用常规方法治疗,治疗组在常规治疗的基础上加用孟鲁斯特(2~6岁为4mg/d,6~ 13岁为5mg/d,睡前口服)治疗,两组进行疗效比较.结果 对照组显效40例,有效5例,无效15例;治疗组显效50例,有效9例,无效1例,治疗组加用孟鲁司特后疗效更优(P<0.05).结论 白三烯受体参与过敏性紫癜的发病过程,用白三烯受体拮抗剂孟鲁斯特治疗过敏性紫癜疗效确切,无明显不良反应.
目的 研究白三烯受體拮抗劑孟魯斯特治療小兒過敏性紫癜的臨床療效.方法 將120例過敏性紫癜患兒隨機分成兩組,對照組採用常規方法治療,治療組在常規治療的基礎上加用孟魯斯特(2~6歲為4mg/d,6~ 13歲為5mg/d,睡前口服)治療,兩組進行療效比較.結果 對照組顯效40例,有效5例,無效15例;治療組顯效50例,有效9例,無效1例,治療組加用孟魯司特後療效更優(P<0.05).結論 白三烯受體參與過敏性紫癜的髮病過程,用白三烯受體拮抗劑孟魯斯特治療過敏性紫癜療效確切,無明顯不良反應.
목적 연구백삼희수체길항제맹로사특치료소인과민성자전적림상료효.방법 장120례과민성자전환인수궤분성량조,대조조채용상규방법치료,치료조재상규치료적기출상가용맹로사특(2~6세위4mg/d,6~ 13세위5mg/d,수전구복)치료,량조진행료효비교.결과 대조조현효40례,유효5례,무효15례;치료조현효50례,유효9례,무효1례,치료조가용맹로사특후료효경우(P<0.05).결론 백삼희수체삼여과민성자전적발병과정,용백삼희수체길항제맹로사특치료과민성자전료효학절,무명현불량반응.
Objective To investigate the clinical effects of Montelukast in treating Henoch-Schonlein purpura children.Methods 120 children with Henoch-Schonlein purpura were randomly divided into two groups.The control group was treated with conventional medication.The treatment group was treated with montelukast sodium (2 ~ 6 year-old given 4 mg/d,6 ~ 13 year-old given 5 mg/d,per os before sleep) in addition.The clinical effects of the two groups were compared.Results The cure rate of treatment group was obviously higher than that of the conventional group (P < 0.05).The clinical effect in the control group:excellent 40 cases,utility 5 cases,ineffective 15 cases; the clinical effect in the treatment group:excellent 50 cases,utility 9 cases,ineffective 1 case.Conclusion There is a close relationship between leukotriene receptor expression in Henoch-Schonlein purpura,leukotriene receptor antagonist is effective in treatment of Henoch-Schonlein purpura,with no obvious adverse reaction.